Sulfasalazine Market Size and Growth Rate?
- As per Data Bridge Market Research analysis, the Sulfasalazine Market was valued at USD 428.0 million in 2025 and is projected to reach USD 627.5 million by 2033, growing at a CAGR of 4.90% from 2026 to 2033.
- The market is experiencing steady growth driven by sulfasalazine's sustained role as a low-cost, first-line conventional DMARD for rheumatoid arthritis and as a maintenance therapy for inflammatory bowel disease, alongside its continued inclusion on the WHO Model List of Essential Medicines.
- Persistently high global prevalence of rheumatoid arthritis and inflammatory bowel disease, combined with sulfasalazine's continued affordability relative to biologic therapies, continues to sustain demand. Recent stabilization of generic manufacturer supply, following a shortage period that began in 2020, is expected to further support consistent market growth.
Market Size & Forecast
- Global Market Value (2025): USD 428.0 Million
- Expected Market Value (2033): USD 627.5 Million
- Forecast CAGR (2026–2033): 4.90%
- Leading Region in 2025: North America
- Fastest Growing Region: Asia-Pacific
What are the Major Takeaways of the Sulfasalazine Market?
- North America dominated the Sulfasalazine Market with the largest revenue share of 34.85% in 2025, supported by established rheumatology and gastroenterology treatment infrastructure and consistent generic manufacturer supply.
- Asia-Pacific is expected to be the fastest-growing region at a CAGR of 6.40% from 2026 to 2033, fueled by rising diagnosis rates for rheumatoid arthritis and inflammatory bowel disease and expanding generic manufacturing capacity across India and China.
- The enteric-coated/delayed-release tablets segment led the dosage form category with a 54.70% share in 2025, owing to its improved gastrointestinal tolerability.
- The oral suspension segment is the fastest-growing dosage form, projected to register a CAGR of 6.35%, reflecting rising pediatric use.
- The rheumatoid arthritis segment dominated the application category with a 41.85% revenue share in 2025, supported by sulfasalazine's established first-line DMARD role.
- The ulcerative colitis segment is the fastest-growing application, with a projected CAGR of 6.10%, driven by rising global inflammatory bowel disease incidence.
- The generic segment accounted for 89% of the market share in 2025, reflecting sulfasalazine's decades-long off-patent status and broad multinational generic manufacturing base.
Report Scope and Sulfasalazine Market Segmentation
|
Attributes |
Sulfasalazine Key Market Insights |
|
Segments Covered |
|
|
Countries Covered |
North America
Europe
Asia-Pacific
Middle East and Africa
South America
|
|
Key Market Players |
|
|
Market Opportunities |
|
|
Value Added Data Infosets |
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework. |
What is the Key Trend in the Sulfasalazine Market?
- Ongoing real-world pharmacovigilance research continues to refine understanding of sulfasalazine's long-term safety profile, informing updated clinical monitoring practices.
- In September 2024, researchers published a large-scale pharmacovigilance study in Frontiers in Pharmacology analyzing FDA FAERS adverse event data from 2004 to 2023, confirming known reactions such as Stevens-Johnson syndrome and agranulocytosis while identifying novel signals including hepatosplenic T-cell lymphoma.
- Manufacturer supply chains for established generic DMARDs continue to stabilize following a multi-year shortage period, improving product availability across major markets.
- In May 2025, updated ASHP drug shortage bulletins confirmed that both Teva and Viatris had resumed consistent supply of sulfasalazine tablets, following a shortage that had been listed on the FDA's drug shortage database since April 2020.
- Continued academic and clinical interest in sulfasalazine's mechanism and expanded use cases reflects its ongoing relevance within conventional DMARD therapy.
- In August 2024, a case report published in the journal Medicine highlighted sulfasalazine's potential role in managing treatment-related rheumatoid nodules, underscoring continued clinical interest in expanding its recognized use cases.
As generic manufacturer supply continues to stabilize and pharmacovigilance research further refines its long-term safety profile, sulfasalazine is expected to retain a durable role within rheumatology and gastroenterology treatment protocols worldwide.
What are the Key Drivers of the Sulfasalazine Market?
- Sulfasalazine's continued inclusion on the WHO Model List of Essential Medicines and its established role as a first-line conventional DMARD sustains demand across both developed and emerging healthcare systems.
- Sulfasalazine has been included on the WHO's Model List of Essential Medicines since at least the organization's 21st list, published in 2019, reinforcing its continued procurement in public health systems globally.
- The persistently high global prevalence of rheumatoid arthritis and inflammatory bowel disease continues to sustain baseline demand for cost-effective, well-established DMARDs such as sulfasalazine.
- In September 2024, a pharmacovigilance study published in Frontiers in Pharmacology analyzed 7,156 sulfasalazine-related adverse event reports submitted to the FDA's FAERS database between 2004 and 2023, reflecting the medication's extensive real-world use across autoimmune and inflammatory bowel disease populations.
- Resolution of prior supply constraints among major generic manufacturers continues to support consistent sulfasalazine availability across major markets.
- In May 2025, updated ASHP drug shortage bulletins confirmed that both Teva and Viatris had resumed consistent sulfasalazine supply, helping stabilize availability following a shortage that had persisted since April 2020.
With rheumatoid arthritis and inflammatory bowel disease remaining significant global health burdens and generic manufacturer supply continuing to stabilize, sulfasalazine is expected to remain a foundational therapy within the broader conventional DMARD and inflammatory bowel disease treatment landscape.
Which Factors are Challenging the Growth of the Sulfasalazine Market?
- Prior supply disruptions have highlighted a limited manufacturer base for sulfasalazine, which can create availability risk during periods of demand fluctuation.
- In April 2020, sulfasalazine (Azulfidine) was added to the FDA's drug shortage database, with both immediate-release and delayed-release formulations affected by supply constraints that persisted for several years before recent stabilization.
- Emerging pharmacovigilance findings continue to identify new potential safety signals, requiring ongoing clinical monitoring that adds complexity to prescribing decisions.
- dermatosis and aseptic meningitis.
- Growing clinical preference for biologic and targeted synthetic DMARDs in developed markets continues to limit sulfasalazine's relative growth compared with newer therapy classes for patients with more severe or treatment-resistant disease.
- The combination of a historically limited manufacturer base, emerging pharmacovigilance monitoring requirements, and growing competition from biologic and targeted synthetic DMARDs continues to create headwinds for the sulfasalazine market, even as its established affordability and essential-medicine status sustain demand globally.
How is the Sulfasalazine Market Segmented?
The Sulfasalazine Market is segmented on the basis of dosage form, application, distribution channel, end user, prescription type, patient care setting, and therapy line.
- By Dosage Form
On the basis of dosage form, the Sulfasalazine Market is segmented into immediate-release tablets, enteric-coated/delayed-release tablets, and oral suspension. The enteric-coated/delayed-release tablets segment dominated the market with a 54.70% share in 2025, owing to its improved gastrointestinal tolerability and widespread preference among prescribers for long-term rheumatoid arthritis and inflammatory bowel disease management.
The oral suspension segment is projected to register the fastest growth at a CAGR of 6.35% from 2026 to 2033, driven by rising use in pediatric patients requiring weight-based dosing for juvenile idiopathic arthritis and inflammatory bowel disease.
- By Application
On the basis of application, the Sulfasalazine Market is segmented into rheumatoid arthritis, ulcerative colitis, Crohn's disease, ankylosing spondylitis, and juvenile idiopathic arthritis. The rheumatoid arthritis segment dominated the market with a 41.85% share in 2025, supported by sulfasalazine's established role as a conventional first-line DMARD and its continued inclusion on the WHO Model List of Essential Medicines.
The ulcerative colitis segment is expected to witness the fastest CAGR of 6.10% from 2026 to 2033, driven by rising global inflammatory bowel disease incidence and sulfasalazine's continued use as a first-line maintenance therapy for mild-to-moderate disease.
- By Distribution Channel
On the basis of distribution channel, the Sulfasalazine Market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The retail pharmacies segment dominated the market with a 46.30% share in 2025, reflecting its role as the primary dispensing channel for long-term outpatient DMARD therapy.
The online pharmacies segment is anticipated to witness the fastest CAGR of 7.20% from 2026 to 2033, supported by expanding digital prescription fulfillment infrastructure for chronic disease medication management.
- By End User
On the basis of end user, the Sulfasalazine Market is segmented into adult, pediatric, and geriatric. The adult segment dominated the market with a 68.75% share in 2025, reflecting the broad prevalence of rheumatoid arthritis and inflammatory bowel disease diagnosis across the general adult population.
The pediatric segment is expected to witness the fastest CAGR of 6.55% from 2026 to 2033, driven by continued use in juvenile idiopathic arthritis and pediatric inflammatory bowel disease management.
- By Prescription Type
On the basis of prescription type, the Sulfasalazine Market is segmented into generic and branded. The generic segment dominated the market with an 88.90% share in 2025, reflecting sulfasalazine's long off-patent status and broad multinational generic manufacturing base.
The branded segment is projected to grow at a comparatively modest CAGR of 3.40% from 2026 to 2033, supported by continued branded prescribing in select markets.
- By Patient Care Setting
On the basis of patient care setting, the Sulfasalazine Market is segmented into outpatient/homecare and inpatient/hospital. The outpatient/homecare segment dominated the market with an 81.20% share in 2025, reflecting sulfasalazine's role as a long-term, self-administered oral maintenance therapy for chronic autoimmune and inflammatory conditions.
The inpatient/hospital segment is expected to witness the fastest CAGR of 5.95% from 2026 to 2033, driven by rising hospital-initiated therapy for newly diagnosed or acute inflammatory bowel disease flares.
- By Therapy Line
On the basis of therapy line, the Sulfasalazine Market is segmented into monotherapy and combination therapy. The combination therapy segment dominated the market with a 57.65% share in 2025, reflecting widespread use of sulfasalazine alongside methotrexate and other conventional DMARDs in rheumatoid arthritis treatment protocols.
The monotherapy segment is projected to grow at a CAGR of 4.25% from 2026 to 2033, supported by continued use as an initial or standalone treatment option for milder disease presentations.
Which Region Holds the Largest Share of the Sulfasalazine Market?
- North America dominated the Sulfasalazine Market and accounted for the largest revenue share of 34.85% in 2025, supported by established rheumatology and gastroenterology treatment infrastructure and consistent generic manufacturer supply following recent shortage resolution.
- The region also benefits from strong insurance-supported access to conventional DMARD therapy, well-established drug safety monitoring frameworks, and continued generic manufacturer engagement with regulators to help stabilize supply. Continued pharmacovigilance research is expected to further reinforce clinical confidence in the region.
U.S. Sulfasalazine Market Insight
The U.S. sulfasalazine market remains anchored by its established role in rheumatoid arthritis and inflammatory bowel disease management, supported by insurance-backed access to low-cost generic DMARD therapy. Following the FDA's April 2020 shortage listing, continued engagement between manufacturers including Teva and Viatris and regulators has helped stabilize supply, as confirmed in ASHP's May 2025 shortage bulletin update.
Canada Sulfasalazine Market Insight
The Canada sulfasalazine market benefits from well-established rheumatology and gastroenterology care infrastructure and continued generic manufacturer supply. Ongoing coordination between regulators and manufacturers continues to support consistent product availability across the country's healthcare system.
U.K. Sulfasalazine Market Insight
The U.K. sulfasalazine market remains well-established, supported by the country's long clinical history with the medication since its introduction in the 1950s and its continued role as a standard conventional DMARD within National Health Service rheumatology treatment protocols.
India Sulfasalazine Market Insight
The India sulfasalazine market benefits from a large domestic generic manufacturing base, including producers such as Zydus, Sun Pharmaceutical, and Cipla, alongside continued government support for affordable essential medicine access. Rising diagnosis rates for rheumatoid arthritis and inflammatory bowel disease continue to support steady domestic and export demand.
China Sulfasalazine Market Insight
The China sulfasalazine market is growing steadily, supported by expanding domestic generic manufacturing capacity, rising healthcare access, and growing diagnosis rates for autoimmune and inflammatory bowel conditions across the country's healthcare system.
Which are the Top Companies in the Sulfasalazine Market?
The global sulfasalazine industry is primarily led by well-established generic and specialty pharmaceutical companies, including:
- Pfizer Inc. (U.S.)
- Viatris Inc. (U.S.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Zydus Lifesciences Ltd. (India)
- Sun Pharmaceutical Industries Ltd. (India)
- Cipla Ltd. (India)
- Alembic Pharmaceuticals Ltd. (India)
- Macleods Pharmaceuticals Pvt. Ltd. (India)
- Cadila Pharmaceuticals Ltd. (India)
- Torrent Pharmaceuticals Ltd. (India)
- Aurobindo Pharma Ltd. (India)
- Lupin Ltd. (India)
- Wockhardt Ltd. (India)
- Sandoz International GmbH (Germany)
- Amneal Pharmaceuticals, Inc. (U.S.)
- Micro Labs Ltd. (India)
- Ipca Laboratories Ltd. (India)
- Strides Pharma Science Limited (India)
What are the Latest Developments in the Sulfasalazine Market?
- In May 2025, ASHP drug shortage bulletin updates confirmed that Teva and Viatris had both resumed consistent supply of sulfasalazine tablets, helping resolve a shortage that had persisted since April 2020.
- In April 2025, researchers published a pharmacovigilance study in Expert Opinion on Drug Safety analyzing 91,509 sulfasalazine-related adverse event reports from the FDA's FAERS database, identifying several previously undocumented safety signals.
- In September 2024, a large-scale pharmacovigilance study published in Frontiers in Pharmacology analyzed FDA FAERS data from 2004 to 2023, confirming established adverse reactions and identifying new potential safety signals for sulfasalazine.
- In August 2024, a case report published in the journal Medicine highlighted sulfasalazine's potential role in managing treatment-related rheumatoid nodules, reflecting continued clinical interest in the drug's expanded use cases.
- In April 2020, sulfasalazine (Azulfidine) was added to the FDA's drug shortage database, with supply constraints affecting both immediate-release and delayed-release formulations for several years before recent stabilization.
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
